New cell therapy player launches with $57M from marquee investors to go after 'definitive' tumor targets
A crew of Amgen and Kite vets is publicly throwing their new startup into the cell therapy hat — though they are saying little outside of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
